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Summary 
A unique experimental model has been developed for dissecting the integrity of CD8 + T  cell- 
mediated immunity to a persistent gammaherpesvirus under conditions of CD4 + T  cell defi- 
ciency.  Respiratory  challenge  of major histocompatibility  complex  class  II  -/-  and  +/+ 
C57BL/6J mice with the murine gammaherpesvirus 68  (MHV-68) leads to productive infec- 
tion of both lung and adrenal epithelial cells. Virus titers peak within 5-10 d, and are no longer 
detected  after  day  15.  Persistent,  latent  infection  is  established  concurrently  in  splenic  and 
lymph node B  cells,  with higher numbers of MHV-68 § lymphocytes being found in all lym- 
phoid sites analyzed from the  +/+  mice concurrent with the massive, but transient splenome- 
galy that occurred only in this group. From day 17, however, the numbers of infected B lym- 
phocytes were consistently higher in the  -/-  group, while the frequency of this population 
diminished progressively in the  +/+  controls.  Infectious MHV-68 was again detected in the 
respiratory tract and the adrenals of the  -/-  (but not the +/+)  mice from day 22 after infec- 
tion. The titers in these sites rose progressively, with the majority of the  -/-  mice dying be- 
tween days 120  and 133.  Even so, some CD8 + effectors were still functioning as late as 100  d 
after infection.  Depletion of CD8 + T  cells at this stage led to higher virus titers in the  -/- 
lung, and to the development of wasting in some of the  -/-  mice. Elimination of the CD8 + 
T  cells from the  +/+  group (day 80)  increased the numbers ofMHV-68 + cells in the spleen, 
but did not reactivate the infection in the respiratory tract. The results are consistent with the 
interpretation that CD8 + T  cell-mediated control of this persistent gammaherpesvirus is pro- 
gressively lost in the absence of the CD4 + T  cell subset. This parallels what may be happening 
in AIDS patients who develop Kaposi's sarcoma and various Epstein Barr virus-associated dis- 
ease processes. 
p ersistent  infection  of human  B  lymphocytes with  the 
prototypic type  1 y-herpesvirus (yHV) 1,  Epstein-Barr 
virus  (EBV),  is thought  to be controlled  by virus-specific 
CD8 +  T  cells  (1-3).  Most  people are  EBV  carriers,  and 
subsequent to the infectious mononucleosis phase that of- 
ten  follows  the  initial  invasion  of the  virus,  normally re- 
main  asymptomatic into  advanced age,  This situation  can 
change  dramatically in  the  immunosuppressed  host  with, 
for  example,  EBV-associated  lymphoproliferative  disease 
being  a  too  common  complication  of therapeutic  bone 
marrow and  organ transplantation  (4-6).  The progression 
of human immunodeficiency virus  (HIV) infection to the 
T  Abbreviations used in this paper: BAL, bronchoalveolar  lavage; BM, bone 
marrow; CLN, cervical lymph node; CMC, carboxymethyt cellulose; 
CMV, cytomegalovirus; EBV, Epstein-Barr virus; 3'HV, 3,-herpesvirus; 
i.n., intranasal; LCMV, lymphocytic choriomeningitis virus; MHV-68, 
mouse ~HV-68; MLN, mediastinaI lymph node; OMK, owl monkey 
kidney (cells). 
AIDS  can  also  be  accompanied  by  the  development  of 
EBV-associated lymphoma, and by the increased excretion 
of EBV from the characteristic oral hairy leukoplakia (7, 8). 
Furthermore,  individuals  with  AIDS  show  a  greatly  in- 
creased incidence  (9)  of Kaposi's sarcoma. Recent analysis 
has implicated a novel type 2 yHV in the  etiology of KS 
(10,  11).  The development of AIDS is associated with de- 
clining  numbers  of CD4 +  T  cells,  the  primary  target  of 
HIV replication (12),  rather than the loss of the CD8 + set 
that is generally considered to be the principal mediator of 
immune surveillance against viruses (13). 
Experimental  dissection  of the  interaction  between  a 
yHV and the CD4 + and CD8 + T  cell responses has been 
made  possible by the  recent  development  of the  murine 
~/HV (MHV-68)  model (17).  Like EBV, this type 2 yHV 
(15,  16) is disseminated as a consequence of the productive 
infection of mucosal epithelial cells  (17).  The viremia that 
occurs during the acute phase of the infection also leads to 
transient virus replication in the thymus and adrenal epithe- 
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numbers of B  lymphocytes  (18).  Selective  elimination of 
the responding CD4 + or CD8 + T  cells in BALB/c (H-2  d) 
mice by in vivo treatment with mAbs has established that 
the initial stage of virus replication in epithelial sites is con- 
trolled  by  CD8 +  effectors  acting  in  the  absence  of the 
CD4 + subset (19).  The characteristic splenomegaly (19, 20) 
was,  however,  greatly  diminished in  the  CD4  +  T  cell- 
depleted mice, and fewer B  cells  could be shown to carry 
the virus. 
The  present  study  extends  this  analysis  to  long-term 
MHV-68  infection of H-2  b  mice  that  are  constitutively 
CD4-deficient as a consequence ofhomozygous disruption 
(-/-)  of the  H  2IA  b  class  II  MHC  glycoprotein  (21). 
Though there  are low numbers of CD4 +  T  ceils in these 
MHC class II -/  animals (2-5% in the periphery), stud- 
ies with a variety of experimental systems have given no in- 
dication that  these  lymphocytes  can  function to  provide 
cognate help for antibody production or to promote CD8 + 
T  cell responses (21-24). 
Materials and Methods 
Mice.  The  +/+  C57BL/6J  (B6) mice were purchased  from 
Jackson ImmunoResearch Laboratories,  Inc.  (Bar Harbor ME). 
The C2D  mice that are  functionally -/-  for the  H-IA  b gene 
(21)  were  bred  under  licence  from  GenPharm  International 
(Mountain View, CA), at St. Jude Children's Research Hospital. 
Female  mice were  infected with MHV-68 at 8-10 wk  of age, 
then maintained under otherwise specific  pathogen-free condi- 
tions in BL3-1evel containment. 
Virus Stocks and Plaque Assay.  The original stock of MHV-68 
(clone G2.4) was obtained from Dr. A.A. Nash at the University 
of Cambridge (Cambridge, UK). The virus  was  grown in owl 
monkey kidney (OMK; 1566CRL, American Type Culture Col- 
lection [ATCC], 1Kockville,  MD) cells maintained in 1KPMI 1640 
(GIBCO BRL, Gaithersburg,  MD) supplemented with 10% FCS, 
2  mM L-glutamine,  and gentamicin. The  OMK cells were  in- 
fected  at  a  multiplicity of infection (MOI)  of 0.01,  and virus 
stocks were prepared  by sonicating the cells in PBS+0.1% BSA 
on ice,  then stored  at  -70~  Uninfected control stocks  were 
prepared  from OMK cells in the same manner. Virus titers were 
determined  by  plaque  assay on  NIH  3T3  cells (ATCC 
CIKL1658) grown in DMEM (GIBCO BRL) supplemented with 
10% FCS, 2 mM 1-glutamine, 4 mM Hepes, and gentamicin. Di- 
lutions of stock  virus,  sonicated mouse  tissues, or  sonicates  of 
lymphocytes were adsorbed onto the NIH 3T3 monolayers for 1 h 
at 37~  then washed with media and overlaid with 2.0 ml ofc0r- 
boxymethyl cellulose (CMC) diluted 1:1 in 2￿  modified Eagle's 
medium supplemented with  10%  FCS,  glutamine,  gentamicin, 
and nonessential amino acids (13). After 5 d, the CMC overlay was 
removed, and the  monolayers fixed  with methanol and stained 
with Giemsa to determine the number of plaques. 
Injection and Sampling.  The mice were anesthetized  (25) with 
Avertin (2,2,2  tribromoethanot), then infected intranasally  (i.n.) 
with 4 x  1.03 PFU of MHV-68 in 40 kcl ofPBS +  0.1% BSA. At 
various  times  after  infection, the  mice were  anesthetized  again 
and bled from the axilla. The inflammatory cells from the lung 
were obtained (25) by bronchoalveolar lavage (BAL), various tis- 
sues were  taken for  virus  isolation,  and single-cell preparations 
were made from the lymph nodes and spleen for cytokine, cyto- 
toxicity,  flow cytometry, and infectious center assays. Peripheral 
blood lymphocytes and bone ,narrow were isolated (13) and ana- 
lyzed for presence of virus. The spleens were first weighed before 
homogenization. The tissues were sonicated in medium on ice, 
and the presence of virus was determined by plaque assay (13). All 
samples were stored at -70~  before virus titration. 
Infectious Center Assay.  The frequency of persistently infected 
lymphocytes was determined by assaying for infectious centers by 
overlaying single-cell  suspensions  oil  monolayers of NIH  3T3 
cells. Various  dilutions of the spleen and lymph node cells were 
plated with 5 ￿  10  ~ NIH 3T3 cells, incubated overnight at 37~ 
and then overlaid  with CMC/2￿  medium. The cells were co- 
cultured for 5-6 d, the overlay was removed, and plaque  counts 
were determined as described  above.  Aliquots  of 107 (or higher) 
spleen or lymph node cells were also sonicated and assayed for the 
presence of infectious virus. 
Redirected Cytotoxicity Assay.  Single-cell suspensions of lymph 
nodes and spleen, or BAL cells that were first adsorbed  on plastic 
to  remove most  of the  macrophages,  were  assayed for  6  h  on 
SlCr-labeled  FcR  + P815  ceils in the presence  of the 2C11  mAb 
to CD3e (26, 27). The level of specific StCr release is a measure 
of the total cytotoxicity mediated by all activated T cells. For as- 
says involving  in vitro depletions,  cell populations were incubated 
with the appropriate  mAb for 30 min at 4~  then the cells were 
washed  and incubated for 45 rain at 37~  in a cocktail  of rabbit 
(Accurate  Chemical and  Scientific  Corp.,  Westbury,  NY)  and 
guinea pig complement (Cedar  Lane Laboratories,  Hornby, On- 
tario). 
Lymphocyte Depletion and Flow Cytometry.  Mice  in  some  ex- 
periments were depleted of CD4 + or CD8 + T  cells by in vivo 
treatment with the GK1.5 or 2.43.1  mAbs, respectively,  which 
were administered for at least 8 d at 2-3-d intervals (25, 28). The 
prevalence of the various lymphocyte subsets was detemfined (29) 
in two-color mode on a FACScan  |  (Becton  Dickinson & Co., 
Mountain View,  CA)  with  Lysis II  software.  The  staining re- 
agents were  53.6.7-FITC anti-CD8c~,  H129.19-PE anti-CD4  § 
and  1KA3-682 FITC  anti-B220,  all  of which  were  purchased 
from Pharmingen (San Diego, CA)  and are not blocked by the 
mAbs used for the in vivo depletions. 
Cytokine Analysis.  The  single-cell  ELISPOT assay was  used 
to quantify cytokine producing cells in freshly isolated BAL pop- 
ulations  (30). Spleen  and lymph node cells were restinmlated in 
vitro with MHV-68-infected stimulator cells (31), and culture 
supernatants  were assayed by ELISA for the presence  of IFN-% 
IL-2,  IL-4, IL-5,  IL-6,  and IL-10,  as described  previously (32). 
The results are expressed as the percentage  of spot-forming cells 
(ELISPOT), or as nanograms (IL-10),  or units per ml of culture 
supernatant (ELISA). 
Results 
Virus  Distribution  during  the  Primary  Stage  of  Infection. 
The  kinetics  and  peak  titers  of the  initial virus  growth 
phase  in  the  respiratory  tract  after  i.n.  inoculation with 
MHV-68  (4  X  103 PFU) were  comparable for the MHC 
class  I1  +/+  and  -/-  mice  (Fig.  I  a).  Lower  titers  of 
MHV-68 were also detected in the adrenals on days 3  and 
6  (Fig.  1 b), and in the thymus on day 6  (data not shown), 
indicating that  the  virus had  disseminated rapidly via  the 
blood in both groups of mice. Even so, the spectrum of or- 
gans supporting productive infection detectable by plaque 
assay appears to be very limited. MHV-68 could not be re- 
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Figure  1.  MHV-68 replication in MHC class II +/+  and -/-  mice: 
infectious virus tilers are shown for the lungs (a) and the adrenal glands (b) 
of the +/+  (I) and -/-  mice ([]). Virus tilers are depicted as the mean 
loglo PFU/ml of a 10% tissue sonicate, (+- SD), for three to five mice per 
timepoint for three to tour separate experiments. Results for single exper- 
iments at 16, 17, 76, 132, and 133 d after infection are also included. The 
limit of detection  for the lung was  1 PFU,  and  5  PFU  for the adrenal 
gland. 
covered during this acute phase from tissue sonicates  of the 
pancreas,  salivary glands, kidney, or liver, (data not shown). 
Replication in the liver and kidneys has been reported for 
BALB/c mice (17). 
This virus does, however, quickly establish a latent infec- 
tion in large numbers orB lymphocytes (19). Cocultivation 
with permissive NIH 3T3 fibroblasts  established  the pres- 
ence of substantial  numbers of cells carrying MHV-68  in 
the  cervical lymph nodes  (CLN)  from day 3,  and in the 
mediastinal lymph nodes  (MLN)  and spleen  from day 6 
(Fig 2,  a-c).  Infectious centers  were  also  detected subse- 
quent to day 15 in the bone marrow (BM,  Fig.  2 d), pe- 
ripheral blood cells, and the mesenteric, axial, and brachial 
lymph nodes (data not shown). The lymph nodes, spleen, 
bone  marrow,  and blood  cells  yielded very few  (or  no) 
plaques  after sonication, indicating that MHV-68  is  pre- 
dominantly in a nonreplicating (or latent) status within the 
lymphoid compartment. 
Virus liters were greatly diminished by day 10 or 13 after 
infection for lung sonicates from the +/+  and -/-  mice, 
respectively, with both being negative by day 15 (Fig. 1 a). 
Similarly,  the adrenal samples were all negative by day 10 
(Fig.  1 b). Despite the termination of the replicative phase, 
however, there was no concurrent decrease in the frequen- 
cies of latently infected B cells (17) in the lymphoid tissue 
(Fig. 2). The numbers ofMHV-68 + cells in the spleens  of 
the -/-  mice (Fig. 2 a) were, however, consistently lower 
through day 15, reflecting that the extent of splenomegaly 
is generally much less in the absence of the CD4 + subset 
(Fig.  3).  In  general,  this  analysis  of the  acute  phase  of 
MHV-68 infection in MHC class II -/-  B6 (H-2  b) mice 
confirms and extends the conclusions reached from earlier 
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Figure  2.  Profiles of MHV-68 la- 
tency are shown for lymphoid tissues 
from  the  +/+  and  -/-  mice. 
Lymphocytes from  the  (a)  spleens; 
(b) MLN;  (c), CLN;  and (d) BM  of 
+/+  (I)  and -/-  ([~)  mice were 
isolated at different times after infec- 
tion for infectious center assay.  The 
results  are  depicted  at  the  mean 
number (+ SD) of infectious centers 
per  107  lymphocytes  pooled  from 
three to five mice per timepoint for 
repeat or single experiments (see leg- 
end to Fig. 1). Timepoints where no 
infectious centers were detected are 
indicated  by  asterisks.  Otherwise, 
timepoints with no data indicate that 
the samples were not assayed. 
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Figure 3.  The extent of sple- 
nomegaty  was  determined  by 
weighing  spleens from  +/+ 
(I) and -/-  ([~) nfice at dif- 
ferent timepoints after MHV-68 
infection. The spleens were into 
preweighed tubes, and the results 
are  expressed as  mean  (+  SI)) 
spleen weight (grams) for groups 
of three  to  five mice per time- 
point.  Spleens  from  uninfected 
(UN) and  mock-infected  (MK) 
nfice were measured for control 
weights, but were  not included 
for each timepoint. 
26).  An important addition to these studies is that all the 
lymph nodes, the bone marrow, and peripheral blood cells 
harbor  latent  virus,  indicating  that  these  persistently  in- 
fected cells are widely disseminated in the infected mouse. 
Characteristics of the Acute Host Response.  The fall in lung 
MHV-68  titers  (Fig.  1  a)  was  accompanied by a  dramatic 
increase (Fig. 4, c and d) in the magnitude of the cell popu- 
lation  recovered  by  BAL.  The  inflammatory  cells  were 
generally more than 30% monocyte/macrophages, with the 
remaining lymphocyte population being dominated by the 
CD8 + subset (Fig. 4, a and b).  In the  +/+  mice, the lower 
numbers of CD4 + T  cells and few B220 + B  ceils are con- 
sistent with  the pattern found for other virus infections of 
the respiratory tract  (25,  28, 33).  As yet, there is no repro- 
ducible virus-specific CTL assay developed for MHV-68. 
Measuring the  cytotoxic activity of all CD3e + T  cells by 
the  redirected  CTL  assay  (26,  27),  however,  showed  the 
emergence of potent effectors in the BAL by day 10 (Fig. 5 
a).  The levels of lysis were higher for the MLN  and spleen 
(Figs. 5, b and c), which, though they are not supporting vi- 
rus  replication  (Fig.  1),  they do  contain large  numbers of 
latently infected  B  lymphocytes  (Fig.  2).  Antibody deple- 
tion experiments with the  +/+  mice showed that the ma- 
jority of this CTL activity is mediated by CD8 + T  cells, but 
the  CD4 +  T  cells may also  be  making some  contribution 
(Fig. 5  d and Table 1). 
Previous experiments with MHV-68  in +/+  mice have 
shown that the cytokine response to this virus is dominated 
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Figure 4.  The characteristics of the inflam- 
matory response in the lung are shown for the 
MHV-68-infected +/+ and -/-  mice. The 
BAL  population  was  collected  and  pooled 
from three to five mice per timepoint ill sin- 
gle or repeat experiments (see to Fig. 1). After 
absorbance  on  plastic dishes, cell numbers 
were  determined  (c and d)> and the  samples 
were analyzed by flow cytomet~" (,i and b). 
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Figure  5.  Effector CTL activ- 
ity from the +/+  (m-) and -/- 
(~3) mice was determined as spe- 
cific SlCr release  (6-h  assay) for 
freshly isolated BAL, MLN,  and 
spleen  populations  (at-,  respec- 
tively)  incubated  with  FcR_  + 
P815  targets  binding  the  2Cll 
mAb  to  CD3-e  (redirected  as- 
say),  at  an  E/T  of 40:1.  Time- 
points through 70  d  after infec- 
tion  are  from  two  separate 
experiments with  three  to  five 
mice per group,  the day 90  re- 
sults  are for a single experiment 
with  three  to  five  mice  per 
group, while the day  133  results 
represent separate assays of three 
mice per group.  (d)  Freshly iso- 
lated  BAL  and  spleen  popula- 
tions  were  depleted  of  CD4 + 
(m)  or  CD8 +  (V1) lymphocytes 
by  in  vitro  treatment  with  the 
GK1.5  or 2.43,1  mAbs, respec- 
tively,  followed  by  incubation 
with  a  cocktail  of  rabbit  and 
guinea  pig  complement.  Frac- 
tions of the cells were either un- 
treated (nondepleted)  or treated with complement alone (mock). Results represent the means (+ SD) of three separate experiments for nondepleted, C1)4- 
depleted, and CDS-depleted samples,  The mock treatment results are from two separate experiments. 
Table  1.  T Cell Depletion of Persistently Infected Mice 
Percent of 
specific 
Infectious centers$  SlCr release  Cytokines 
Virus titer in lung 
Group  Treatment  (log10 PF U/ml)  Spleen  MLN  CLN  BAL  Spleen  IL-6  IFN-y 
U/ml 
-/-  Saline  0.98  +  0.30  70  194  39  35.0  7.4  9.6  0 
Day 84  CD4  1.43  +  0,58  60  88  40  ND  18.0  16.2  2.3 
CD8-  3.66  _+  0,58*  170  191  442  ND  7.3  15.3  3.2 
-/-  Saline  2.2  +  0.04  130  (12.4  _  9.75)  43.4  7.7  12.4  +  16.1  0 
Day 114  CD8-  3.7  +  1.2"  150  (51.2  +  47.8)  ND  0  30.9  •  21.5  0 
+/+  Saline  0  4  (0)*  44.5  32.9  9.6  +  21.5  31.5  +_  37.1 
Day 80  CD4  0  6  (0)  38.4  26.9  22.6  +  4.7*  8.1  +_  6.8 
CD8-  0  52  (1.6  +  0.8)*  17.6  10.1  29.7  •  12.7"  83.5  +  55.0* 
The mice were treated with the GK1.5 mAb to CD4, the 2.43.1  mAb to CD8, or with saline at 2-3-d intervals commencing 10 d before sampling. 
The percent of CD8 + T  ceils in the spleens of the CD8-depleted mice were 0.3 (day 84), 0.5 (day 114), and 1.3 (day 80)_ The CD3e-dependent 
CTL assay (26, 27) is described in the legend to Fig. 5. Cytokines (mean _+ SD) were measured by ELISA of cu]ture supernatants from restimulated 
spleen cells as described in the legend to Fig. 6. 
*Significantly different (P <0.05 or <) from the saline control by Wilcoxon rank analysis (virus data) or, for the cytokine results, Mann U. Whitney 
rank sum, test or Student's t test, depending on whether the data was nomlally distributed. 
*The day 84 results show infectious centers per 10 v cells from pooled spleen, MLN, or CLN populations (five mice per group). The results at the 
other timepoints are for pooled (per 107 cells)  or individual (per 10  f' cells, mean -+ SD, in parentheses) spleen cells.  At day 114,  -/-  results are for 
five mice (+ saline) and four mice (CD8-), one of which was severely debilitated and was harvested on the previous day. At day 80, the +/+  results 
are for six mice (+ saline) and five mice (CDS-). 
ND, not done because ofinsu~cient cell numbers. 
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Figure  6.  The  cytokine pro- 
duction  profiles are  shown for 
MHV-68-infected  +/+  and 
- / -  mice. Freshly isolated sple- 
nocytes from infected +/+  (I) 
and  -/-  ([])  mice were cul- 
tured with irradiated, MHV-68- 
infected (MOI  =  (}.01) spleno- 
cytes  isolated from  uninfected 
mice as APCs. The lymphocyte 
cultures were incubated at 37~ 
and supernatants were collected 
at 24, 72, and 96 h after infection 
for  detection  of cytokine pro- 
duction by ELISA  (31). (a) IFN-y 
and IL-6 were measured in cul- 
ture supernatants by ELISA. Re- 
suits are  expressed as the  mean 
units of IFN-'y or IL-6 per nil su- 
pematant after 72  h of stimula- 
tion. Little or no IL-2, IL-4, or 
IL-5 was detected. (b) Frequen- 
cies of IFN-y-producing cells in 
BAL  populations  were deter- 
mined using the ELISPOT tech- 
nique (30). 
by CD4 +  T  cells  producing IFN-'y and  several  cell  types 
(including  acutely  infected  B  lymphocytes)  making  IL-6 
(reference 31  and unpublished data).  This pattern was con- 
firmed  in  the  present  study,  with  the  amounts  of IFN-~/ 
that could be detected after in vitro restimulation of spleen 
cells from the  -/-  mice being much lower, while the lev- 
els of IL-6 were comparable for the two groups (Fig. 6  a). 
In  contrast  to  the  results  for  the  spleen,  the  numbers  of 
IFN-',/-producing  cells  detected  by  single-cell  ELISPOT 
analysis  of the  BAL were  similar  for the  +/+  and  -/- 
mice (Fig. 6  b). Activated CD8 § T  cells  are generally con- 
sidered  to  produce  IFN-y,  but  at  a  lower level  than  the 
CD4 +  subset.  If this  ELISPOT  analysis  is  assaying virus- 
specific  effectors,  the  prevalence  in  the  BAL at  the  acute 
phase of MHV-68 infection is in the range of 1:20 for the 
T  cell component in both groups of mice (compare Figs. 4 
and 6 b). Analyzing sorted CD8 + T  cells from the BAL has 
not been successful (data not shown), perhaps because these 
highly activated lymphocytes require  support from mono- 
cyte/macrophages for survival during the  24-h incubation 
time of the ELISPOT assay  (30). 
Virus Reactivation and Persistence.  Virus  was  again  de- 
tected  consistently  in  lungs  and  adrenals  from  the  -/- 
mice subsequent to day 22 after the initial challenge, while 
the  only evidence  of virus  replication  in  the  +/+  group 
was a single plaque in a lung sample from day 90 (Fig.  1,  a 
and b). Virus was also detected in the kidneys of one  -/- 
mouse at day 70, even though there was no evidence of vi- 
rus replication  in this  site  during  the  acute infection  (data 
not shown).  Furthermore,  the numbers of latently infected 
cells  in the lymph nodes and spleen  (and peripheral  blood 
cells,  but not the BM) decreased progressively for the  +/+ 
mice,  while  the  counts  stayed  high  for  the  -/-  group 
(Fig. 2). Though the lung titers in the  -/-  group were al- 
ways at least  10-fold lower than in  the  acute phase of the 
disease,  these  mice developed  evidence of wasting and 21 
of 25 died by day  133: the results at the late timepoints in 
Figs.  1-4 are for the few survivors. The  +/+  mice all re- 
mained clinically normal. 
Both the numbers ofCD8 + T  cells in the BAL (Fig. 4, b 
and  d)  and  the  levels  of CD3~-  dependent  CTL  activity 
(Fig. 5  a)  were much higher for the  -/-  mice at the day 
133  timepoint.  This  divergence  from  the  +/+  controls 
was not seen for the spleen  (Fig. 5 c), which contained sig- 
nificant  populations  of latently  infected  B  cells  in  both 
groups (Fig. 2  a).  In other virus models (such as influenza) 
where the virus is rapidly eliminated, this CD3E-dependent 
effector function does not persist beyond 2-3 wk after in- 
fection (Tripp,  P,..A.,  unpublished  data).  Though the total 
numbers ofCD8 + T  cells did not decline (data not shown), 
restimulation  of the  -/-  spleen  cells  in vitro after day 30 
gave  no  indication  of a  significant  IFN-y recall  response 
(Table  1).  Spleen cells  from +/+  mice,  however, contin- 
ued  to  produce  significant  levels  of  IFN-',/  (data  not 
shown), as previously reported (31). 
Maintenance  then  Loss  of CD8 +  T  Cell-mediated  Control. 
Given that the acute phase of MHV-68 infection is termi- 
nated  by  the  CD8 +  subset,  the  obvious  question  was 
whether the reactivation or reappearance of infectious virus 
in the lungs and adrenals by day 22 in the -/-  mice (Fig.  1) 
reflected that the CD8 + effectors rapidly become nonfunc- 
tional  in  the  absence  of CD4 +  T  cell  "help."  There  is  a 
precedent  for  thinking  that  such  "immune  exhaustion" 
(34,  35)  can  occur  from  experiments  with  lymphocytic 
choriomeningitis virus (LCMV). 
Depleting the  -/-  mice with the 2.43.1  mAb to CD8 + 
commencing at 74 or 104 d  after infection established that 
there is still some CD8 + T  cell-mediated control of MHV- 
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iment  (day  84,  Table  1),  removing  the  CD8 +  T  cells 
caused a  >40-fold increase in lung virus titers within  10 d 
of commencing the mAb treatment,  compared with a >3- 
fold effect in -/-  mice given the GK1.5 mAb to CD4 + as 
a  control.  The repeat  experiment  showed a  >30-fold in- 
crease  after in vivo elimination  of the CD8 + subset in the 
-/-  mice (day 114, Table  1), while no virus was detected 
in lung sonicates from +/+  controls that were treated con- 
currently (Table  1).  Only the CDS-depleted  -/-  animals 
showed any signs of obvious debility and, in the second ex- 
periment,  the mice were weighed every 2 d to confirm the 
impression of wasting. All -/-  mice exhibited weight loss 
after treatment  with the  2.43.1  mAb, with one decreasing 
40% within 6 d. This mouse was sampled 1 d early, and had 
the  highest  lung virus  titer  yet recorded  (105) during  the 
phase of MHV-68 reactivation (data not shown). 
The numbers oflatently infected B  cells  in -/-  pooled 
spleen populations also tended to increase after the removal 
of the  CD8 +  subset  (day 84  and  114,  Table  1),  with  this 
treatment  being  statistically  significant  for the  +/+  mice 
that  were  analyzed on day 80  (Table  1).  The  +/+  mice 
also  showed  evidence  of reduced  CD3~-dependent  CTL 
activity in the BAL and spleen after both CD4 + and CD8 + 
T  cell depletion,  but only the latter treatment  had any ef- 
fect on the frequency ofMHV-68 + B cells, which were still 
much less prevalent compared to the -/-  mice (Table 1).  It 
thus seems that the numbers of persistently infected B  ceils 
are  being  continuously  controlled  by  CD8 +,  but  not 
CD4 +,  effectors.  However,  this  CD8 +  T  cell surveillance 
function becomes progressively compromised in the long- 
term absence of the CD4 + subset. 
Discussion 
No comparable generalized recrudescence of a DNA vi- 
rus infection has been described for any rodent model. De- 
pleting CD4 + T  cells with an appropriate  mAb led to de- 
fective  control  of murine  cytomegalovirus  (CMV)  in  the 
salivary gland,  and  to  reactivation  after  such  treatment  of 
latently infected mice  (36,  37,  13).  Unlike MHV-68  (19), 
systemic  CMV infection  can be  limited  by CD4 +  T  cells 
acting in the absence of the CD8 + subset (38). The effector 
mechanism is IFN-y dependent,  with CMV dissemination 
during recurrent infection being facilitated by subversion of 
the specific antibody response.  Failure to neutralize MHV- 
68 could be contributing to the progressive involvement of 
new B  lymphocyte and epithelial cell targets in the MHV- 
68-infected MHC  class  II -/-  mice.  However,  the con- 
sequences of eliminating the CD8 + subset late in the course 
of MHV-68 infection are such that, even if the lack of anti- 
body is allowing indolent virus to spread,  the extent of the 
infectious process is still  being limited by the  CD8 + effec- 
tor population for some months. 
It  is  known  that  concurrent  CD4 +  T  help  can  some- 
times,  though not always,  have  a  significant  effect on the 
acute clonal expansion and differentiation of the virus-spe- 
cific CD8 + population (33). The CD8 + T  cell response af- 
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ter infection with Herpes simplex virus was substantially di- 
minished  by  mAb  depletion  of  the  CD4  +  subset 
commencing before  virus  priming  (39).  The  -/-  mice 
used here developed fewer virus-specific CD8 + CTL pre- 
cursors  after  infection  with  an  influenza  A  virus  (24), 
though clearance from the lung was not compromised (24, 
40),  and the acute CTL response to LCMV and to Sendal 
virus was substantially normal (41, 42). Results from the in- 
fluenza  experiments  suggests  that  the  smaller  numbers  of 
CTL precursors were transiently consumed to give a suffi- 
cient population of CTL effectors (24).  Comparable  cyto- 
kine  profiles  were  found  for  -/-  mice  infected  acutely 
with  Sendal  virus  or influenza  virus,  though  the  level  of 
IFN-y production was much higher for the  Sendal model 
(24, 42). 
The requirement for the CD4 + subset to sustain effective 
CD8 + T  cell surveillance  in the  MHV-68  model is likely 
to reflect that the  "helpers"  function continuously to pro- 
vide a cytokine-rich milieu in responding lymphoid tissue. 
P,  estimulation  of lymphocyte populations  from MHV-68 
infected  +/+  mice has  shown the  long-term presence  of 
IFN-y-producing T  cells  (31).  Little  IL-2 is detected,  and 
there  is no tendency for IL-4 producers  to emerge in  the 
long-term  in  either  the  +/+  or  -/-  mice  (data  not 
shown). The cytokines may be promoting continued clonal 
expansion of the CD8 + responder population, or diminish- 
ing  the  extent  of effector  T  cell  loss  by  (for  example) 
blocking apoptosis. The in vivo dissection of rates of virus- 
specific T  cell production and loss presents  major difficul- 
ties  with  even  the  well-established  viral, models  (43,  44), 
and is clearly not feasible  at  this  early stage of the  analysis 
with MHV-68. 
Like  MHV-68  (19),  LCMV  cannot  be  eliminated  by 
CD4 +  T  cells  acting  in  the  absence  of the  CD8 +  subset 
(45,  46).  Mice infected with macrophage or lymphotropic 
variants  of LCMV develop a persistent  infection, which is 
eventually  cleared  in  normal  mice,  but  not  in  CD4- 
depleted  mice  (35).  The  progressive  exhaustion  of  the 
CD8 +  subset  in this  and in the  "high virus  dose  immune 
paralysis" model of LCMV infection (34)  has obvious par- 
allels  to the events that we describe here in the MHC  class 
II  -/-  mice infected with MHV-68.  The differences are 
that LCMV is known to infect a wide variety of cell types 
in vivo, (including a percentage oft  lymphocytes), but un- 
like  the  herpesviruses,  this  1LNA virus  has  no  mechanism 
for establishing latent infection. 
It is not clear whether the MHV-68 replicative phase in 
the lung and the latently infected B cells in lymphoid tissue 
are controlled by the same or different sets of virus-specific 
effectors  (47),  and  will  not  be  understood  until  at  least 
some of the epitopes recognized by the responding T  cells 
are defined. The mAb depletion experiments with BALB/c 
mice  (19)  had  already  established  that  the  termination  of 
the acute, replicative phase in epithelial sites  is mediated by 
the  CD8 +  subset.  Even  so,  the  larger numbers  of MHV- 
68 + B  cells  in the persistently infected  -/-  mice may re- 
flect that  MHC  class  II-restricted  CD4 +  effectors operate 
to limit the extent of infection in the normal  +/+  animal. However,  treating  the  persistently-infected  +/+  mice 
with an mAb to the CD8 + but,  not the CD4 +, subset in- 
creased the numbers  ofMHV-68 + B  cells. Though  CD4 + 
CTL  can be shown  to develop after the infection of mice 
that  lack  MHC  class  I  glycoproteins with  (for  example) 
LCMV and Sendai virus (48, 49), there is currently no evi- 
dence  that such effectors are functioning directly to elimi- 
nate latently infected B  cells in the MHV-68 model. 
Infection  of MHC  class  II  -/-  mice  with  MHV-68 
thus  offers a  unique  experimental system for assessing the 
mechanisms  that  underlie  compromised  immune  surveil- 
lance in a model of viral latency, and for screening possible 
chemotherapy-, cytokine-, or cell-based protocols to limit 
yHV-associated disease. This is the first time that we have 
had  the  opportunity to  analyze experimentally a  situation 
where  there  is  continuing  control  of  a  DNA  virus  by 
CD8 +  effectors. The  fact that the progressive escape from 
effective  surveillance by  CD8 +  T  cells is  a  direct  conse- 
quence  of the  absence  of the  CD4 +  subset  offers a  direct 
parallel to the situation in AIDS. 
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